
Supriya Lifescience Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Revenue expected to be higher in H2 FY25 compared to H1, with new product launches in Q3 gaining traction in non-regulated markets.
- Whey protein project awaiting FSSAI license, expected by end of Q3, adding to revenue.
- CMO/CDMO opportunities, particularly in formulation and API advanced intermediates, expected to start commercial revenue from Q4 FY25 or Q1 FY26.
- Ambernath formulation contract manufacturing facility to begin revenue generation from Q4 FY25 or Q1 FY26.
- Base case revenue target for FY27 is Rs. 1,000 crore, with potential upside to Rs. 1,200 crore due to higher utilization and new product traction.
- New product launches expected to contribute around 15% of topline in 2 years.
- Continued strong growth in regulated markets including LATAM, Europe, and North America.
- Capacity expansion (Module E and Ambernath) expected to reach full utilization by end FY27, supporting 20%+ year-on-year revenue growth.
See what Supriya Lifescience management said on margin guidance — free account, 30 seconds.
Fundraise plans
- Currently, Supriya Lifescience Limited is following a conservative borrowing approach, primarily using letters of credit and bank guarantees without tapping into working capital limits.
- For the current year, CAPEX plans are focused on completing module E and the Ambernath facility, with about Rs. 100 crore planned for repairs of modules A, B, and C over phases.
- There is no immediate indication of new debt or equity fundraising planned; next major expansion at Patalganga is considered 2.5 to 3 years down the line.
- No mention of any new fundraising through equity or debt in the near term during the conference.
- The company seems focused on organic growth and efficient use of existing financial resources while maintaining a strong financial position with a very low debt-to-equity ratio of 0.01.
See what Supriya Lifescience management said on order book — free account, 30 seconds.
Capex plans
Yes- Current year CAPEX focuses on completing Module E and Ambernath facility.
- Planned maintenance CAPEX for existing modules A, B, and C, estimated around Rs. 100 crore over phases.
- No major CAPEX beyond this is anticipated in the near term.
- Next significant expansion wave likely in 2.5 to 3 years, targeting Patalganga site.
- Module E expansion adds about 400 KL capacity; Ambernath adds about 70 KL, totaling approx. 1,020 KL capacity.
- Commercial production from Module E began in Q3; full utilization expected by end of FY27.
- Operating expenses related to new facilities will increase by a few crores per quarter due to staffing and power costs but offset partially by solar power savings.
Track Supriya Lifescience — get its next earnings analysis in your feed
How does Supriya Lifescience rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Supriya Lifescience rank in Pharmaceuticals & Biotechnology?
Compare Supriya Lifescience against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Supriya Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem